BioSpace News Archive

CV Sciences, Inc., a preeminent supplier and manufacturer of hemp cannabidiol products, announced its financial results for the quarter ended September 30, 2020.

Rigel Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2020, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Sonata Scientific LLC, a developer of advanced air purification and antimicrobial products, has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000 to conduct research

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company will arrange a virtual capital markets day for investors, analysts and journalists on November 30 th , 2020. The program will be published on the company’s website during the week of November 23 at: www.oncopeptides.com/en/calendar/ Oncopeptide

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that chief executive officer Shawn O’Connor will be participating in the Credit Suisse 29 th Annual Virtual Healthcare Conference on Tuesday, November 10, 2020. Mr. O’Connor’s presentation will begin at 3:30 p.m. ET and will be webcast live.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it has broadened its Expanded Access Program (EAP)

InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, announced today that the company will present latest clinical data of its BTK inhibitor Orelabrutinib at the 62 nd American Society of Hematology (ASH) Annual Meeting on December 5-8, 2020, which will be held online. The study in Patients with Relapsed or Refrac

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the upcoming 62 nd Annual American Society of Hematology (ASH) meeting being held virtually December 5-8, 2020. Poster presentation details: Poster Title: The Crimson

Assemblywoman Latrice Walker and Councilwoman Alicka Ampry-Samuel work with Medly Pharmacy and EmblemHealth to make sure New Yorkers receive the Flu Vaccine

The new initiative will fuel collaboration and discovery about the biology of Down syndrome and its co-occurring medical conditions